Nanobiotix (NBTX) has reported its latest voting rights and share capital status as of May 31, 2025. The company disclosed that it has 47,426,851 shares outstanding. The total number of theoretical voting rights stands at 49,529,244, while the exercisable voting rights amount to 49,507,126. This regular update, required by French regulatory authorities, provides transparency regarding the company's capital structure and voting rights distribution. The disclosure complies with the French Commercial Code and the General Regulation of the French Financial Markets Authority (AMF).
Nanobiotix (NBTX) ha comunicato il suo pi霉 recente stato dei diritti di voto e del capitale sociale al 31 maggio 2025. La societ脿 ha dichiarato di avere 47.426.851 azioni in circolazione. Il numero totale di diritti di voto teorici 猫 pari a 49.529.244, mentre i diritti di voto esercitabili ammontano a 49.507.126. Questo aggiornamento periodico, richiesto dalle autorit脿 regolatorie francesi, garantisce trasparenza riguardo alla struttura del capitale e alla distribuzione dei diritti di voto della societ脿. La comunicazione 猫 conforme al Codice Commerciale francese e al Regolamento Generale dell鈥橝utorit脿 dei Mercati Finanziari (AMF).
Nanobiotix (NBTX) ha informado sobre su estado m谩s reciente de derechos de voto y capital social al 31 de mayo de 2025. La compa帽铆a declar贸 que tiene 47.426.851 acciones en circulaci贸n. El n煤mero total de derechos de voto te贸ricos es de 49.529.244, mientras que los derechos de voto ejercitables ascienden a 49.507.126. Esta actualizaci贸n peri贸dica, requerida por las autoridades regulatorias francesas, proporciona transparencia sobre la estructura de capital y la distribuci贸n de los derechos de voto de la empresa. La divulgaci贸n cumple con el C贸digo de Comercio franc茅s y el Reglamento General de la Autoridad de Mercados Financieros (AMF).
Nanobiotix (NBTX) a communiqu茅 son dernier 茅tat des droits de vote et du capital social au 31 mai 2025. La soci茅t茅 a d茅clar茅 d茅tenir 47 426 851 actions en circulation. Le nombre total de droits de vote th茅oriques s'茅l猫ve 脿 49 529 244, tandis que les droits de vote exer莽ables sont de 49 507 126. Cette mise 脿 jour r茅guli猫re, exig茅e par les autorit茅s r茅glementaires fran莽aises, assure une transparence sur la structure du capital et la r茅partition des droits de vote de l'entreprise. Cette divulgation est conforme au Code de commerce fran莽ais et au R猫glement g茅n茅ral de l'Autorit茅 des march茅s financiers (AMF).
Nanobiotix (NBTX) hat seinen aktuellen Stand der Stimmrechte und des Aktienkapitals zum 31. Mai 2025 gemeldet. Das Unternehmen gab bekannt, dass 47.426.851 Aktien im Umlauf sind. Die Gesamtzahl der theoretischen Stimmrechte betr盲gt 49.529.244, w盲hrend die aus眉bbaren Stimmrechte 49.507.126 betragen. Dieses regelm盲脽ige Update, das von den franz枚sischen Aufsichtsbeh枚rden verlangt wird, sorgt f眉r Transparenz bez眉glich der Kapitalstruktur und der Verteilung der Stimmrechte des Unternehmens. Die Offenlegung erfolgt in 脺bereinstimmung mit dem franz枚sischen Handelsgesetzbuch und der Allgemeinen Verordnung der franz枚sischen Finanzmarktaufsicht (AMF).
Positive
None.
Negative
None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit茅 des March茅s Financiers)
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company鈥檚 philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at or follow us on and .
_____________________ 1The total number of theoretical (or 鈥済ross鈥�) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2The total number of exercisable at a shareholders鈥� meeting (or 鈥渘et鈥�) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
What is the current number of outstanding shares for Nanobiotix (NBTX)?
As of May 31, 2025, Nanobiotix has 47,426,851 shares outstanding.
How many voting rights does Nanobiotix (NBTX) have as of May 2025?
As of May 31, 2025, Nanobiotix has 49,529,244 theoretical voting rights and 49,507,126 exercisable voting rights.
What is the difference between theoretical and exercisable voting rights for NBTX?
Theoretical voting rights (49,529,244) include all potential votes, while exercisable voting rights (49,507,126) represent the actual votes that can be cast, excluding shares with suspended voting rights.
Where is Nanobiotix (NBTX) stock listed?
Nanobiotix is listed on both Euronext Paris (Compartment B) and Nasdaq, with the ticker symbol NBTX.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
